{"drugs":["Nilotinib Hydrochloride","Tasigna"],"mono":[{"id":"928915-s-0","title":"Generic Names","mono":"Nilotinib Hydrochloride"},{"id":"928915-s-1","title":"Dosing and Indications","sub":[{"id":"928915-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Philadelphia chromosome positive chronic myelogenous leukemia, Accelerated phase, Resistant or intolerant to prior therapy:<\/b> 400 mg ORALLY twice daily, approximately 12 hours apart on an empty stomach (avoid food for 2 hours before and 1 hour after taking nilotinib)<\/li><li><b>Philadelphia chromosome positive chronic myelogenous leukemia, Chronic phase, newly diagnosed:<\/b> 300 mg ORALLY twice daily, approximately 12 hours apart on an empty stomach (avoid food for 2 hours before and 1 hour after taking nilotinib)<\/li><li><b>Philadelphia chromosome positive chronic myelogenous leukemia, Chronic phase, resistant or intolerant to prior therapy:<\/b> 400 mg ORALLY twice daily, approximately 12 hours apart on an empty stomach (avoid food for 2 hours before and 1 hour after taking nilotinib)<\/li><\/ul>"},{"id":"928915-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},{"id":"928915-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>concomitant strong CYP3A4 inhibitors or grapefruit products:<\/b> avoid if possible; if use is necessary, stop nilotinib; if concomitant use is required, reduce the dose of nilotinib to 200 mg once daily (in newly diagnosed cases) or 300 mg once daily (in resistant or intolerant cases); after discontinuation of a strong CYP3A4 inhibitor, a washout period is necessary before increasing the nilotinib dose to the indicated dose; closely monitor for QT prolongation if concomitant use cannot be avoided<\/li><li><b>concomitant strong CYP3A4 inducers or St John's wort:<\/b> avoid if possible; dosage increase of nilotinib is not likely to compensate for reduced exposure<\/li><li><b>QTc interval greater than 480 msec:<\/b> stop nilotinib; correct serum potassium and magnesium levels if below the lower limit of normal to within normal range and review concomitant medications; resume nilotinib at the previous dose if the QTcF returns to less than 450 msec and to within 20 msec of baseline within 2 weeks; reduce the nilotinib dose to 400 mg once daily if the QTcF is between 450 and 480 msec after 2 weeks; if the QTcF returns to levels above 480 msec after the dose reduction to 400 mg once daily, discontinue nilotinib; repeat ECG approximately 7 days after every dose adjustment<\/li><li><b>absolute neutrophil count (ANC) less than 1 x 10(9)\/L and\/or platelet count less than 50 x 10(9)\/L unrelated to underlying leukemia:<\/b> stop nilotinib; resume within 2 weeks at the previous dose once the ANC is greater than 1 x 10(9)\/L and the platelet count is greater than 50 x 10(9)\/L; reduce the dose to 400 mg once daily if the ANC and platelet count remain low for longer than 2 weeks<\/li><li><b>(baseline) hepatic impairment (mild, moderate or severe) in newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia-chronic phase:<\/b> adjust initial dosage to 200 mg twice daily, followed by 300 mg twice daily if tolerated<\/li><li><b>(baseline) hepatic impairment in resistant or intolerant Philadelphia chromosome-positive chronic myeloid leukemia-chronic or accelerated phase:<\/b> mild or moderate, initial, 300 mg twice daily, followed by 400 mg twice daily if tolerated; severe, initial, 200 mg twice daily, followed by 300 mg twice daily then 400 mg twice daily if tolerated<\/li><li><b>(during therapy) hepatic impairment:<\/b> grade 3 or higher bilirubin or transaminase level elevations, stop nilotinib; resume at a dose of 400 mg once daily when levels return to grade 1 or less<\/li><li><b>serum lipase or amylase levels, grade 3 or higher elevations:<\/b> stop nilotinib; resume nilotinib at a dose of 400 mg once daily when serum lipase or amylase levels return to grade 1 or less<\/li><li><b>nonhematological toxicities, other than elevated bilirubin, hepatic transaminase, lipase, or amylase levels, that are clinically significant and moderate or severe:<\/b> stop nilotinib; resume at a dose of 400 mg once daily when the toxicity has resolved; consider increasing the dose back to 300 mg (in newly diagnosed cases) or 400 mg (in resistant or intolerant cases) twice daily if clinically appropriate<\/li><\/ul>"},{"id":"928915-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Philadelphia chromosome positive chronic myelogenous leukemia, Accelerated phase, Resistant or intolerant to prior therapy<\/li><li>Philadelphia chromosome positive chronic myelogenous leukemia, Chronic phase, newly diagnosed<\/li><li>Philadelphia chromosome positive chronic myelogenous leukemia, Chronic phase, resistant or intolerant to prior therapy<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Blastic phase chronic myeloid leukemia, Resistant or intolerant to imatinib<\/li><li>Gastrointestinal stromal tumor, Advanced, resistant to or intolerant of imatinib and\/or sunitinib<\/li><\/ul>"}]},{"id":"928915-s-2","title":"Black Box Warning","mono":"<b>Oral (Capsule)<\/b><br\/>Prolongation of the QT interval and sudden death have been reported. Do not use nilotinib in the presence of hypokalemia, hypomagnesemia, or long QT syndrome. Hypokalemia or hypomagnesemia must be corrected prior to nilotinib administration and monitored during treatment. Avoid drugs that prolong the QT interval and strong CYP3A4 inhibitors. Avoid food 2 hours before and 1 hour after taking nilotinib. ECGs should be obtained to monitor the QTc.<br\/>"},{"id":"928915-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928915-s-3-9","title":"Contraindications","mono":"<ul><li>Hypokalemia; increased risk of QT-interval prolongation<\/li><li>Hypomagnesemia; increased risk of QT-interval prolongation<\/li><li>Long QT syndrome<\/li><\/ul>"},{"id":"928915-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Monitor for QT-interval prolongation, which can progress to torsade de pointes; therapy interruption, dose adjustment, and discontinuation may be required<\/li><li>-- Avoid use in patients with long QT syndrome, hypokalemia, or hypomagnesemia, as QT-interval prolongation and sudden deaths have been reported<\/li><li>-- Avoid concomitant use with QT-prolonging drugs and strong CYP3A4 inhibitors due to risk of additive QT-interval prolongation<\/li><li>-- Avoid eating at least 2 hours before and at least 1 hour after administration due to increased risk of QT-interval prolongation<\/li><li>Cardiovascular:<\/li><li>-- Monitor cardiovascular status, as serious cardiac and arterial vascular occlusive events (eg, ischemic heart disease, peripheral arterial occlusive disease, ischemic cerebrovascular events) have occurred<\/li><li>-- Monitor for severe fluid retention, including pulmonary edema, ascites, pericardial effusion and pleural effusion<\/li><li>-- Use cautiously in patients with cardiac disorders (eg, recent myocardial infarction, congestive heart failure, unstable angina, clinically significant bradycardia)<\/li><li>Endocrine\/Metabolic:<\/li><li>-- Correct electrolyte abnormalities (ie, hypo- or hyperkalemia, hypocalcemia, hypophosphatemia, hypomagnesemia, hyponatremia) before treatment initiation and monitor during therapy<\/li><li>-- Not recommended for patients with hereditary galactose intolerance, severe lactase deficiency and intolerance to lactose, or glucose-galactose malabsorption, as capsules contain lactose<\/li><li>Gastrointestinal:<\/li><li>-- Monitor serum lipase levels, especially in patients with a history of pancreatitis; treatment interruption and dose adjustment may be required<\/li><li>-- Consider more frequent monitoring in patients with total gastrectomy due to decreased nilotinib exposure; dose adjustment or alternative therapy may be necessary<\/li><li>Hepatic:<\/li><li>-- Monitor for hepatotoxicity (eg, elevated bilirubin, AST\/ALT, alkaline phosphatase levels); treatment interruption or dose adjustments may be warranted<\/li><li>-- Monitor and reduce dose in patients with baseline hepatic impairment (mild, moderate, or severe) due to increased risk of QT-interval prolongation<\/li><li>Hematologic:<\/li><li>-- Monitor for myelosuppression (ie, neutropenia, thrombocytopenia, anemia) and withhold or reduce dose if neutropenia or thrombocytopenia occurs<\/li><li>-- Severe hemorrhage from various sites has been reported<\/li><li>Other:<\/li><li>-- Tumor lysis syndrome has occurred<\/li><li>Concomitant Use:<\/li><li>-- Avoid concomitant use with antiarrhythmics or other QT-prolonging drugs due to risk of additive QT interval prolongation; monitoring required and dose adjustment may be warranted if coadministered<\/li><li>-- Avoid concomitant use with strong CYP3A4 inhibitors or grapefruit products due to increase risk of QT interval prolongation; monitoring required and dose adjustment may be warranted if coadministered<\/li><li>-- Avoid concomitant use with strong CYP3A4 inducers or St. Johns's wort<\/li><li>-- Concomitant use with proton pump inhibitors is not recommended<\/li><\/ul>"},{"id":"928915-s-3-11","title":"Pregnancy Category","mono":"Nilotinib: D (FDA)<br\/>"},{"id":"928915-s-3-12","title":"Breast Feeding","mono":"Nilotinib: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"928915-s-4","title":"Drug Interactions","sub":[{"id":"928915-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Colchicine (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Nelfinavir (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"928915-s-4-14","title":"Major","mono":"<ul><li>Abiraterone (theoretical)<\/li><li>Ado-Trastuzumab Emtansine (theoretical)<\/li><li>Afatinib (theoretical)<\/li><li>Alfentanil (theoretical)<\/li><li>Alfuzosin (theoretical)<\/li><li>Aliskiren (theoretical)<\/li><li>Alprazolam (theoretical)<\/li><li>Ambrisentan (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amlodipine (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Amprenavir (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Artemether (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Atorvastatin (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Bosentan (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Brentuximab Vedotin (theoretical)<\/li><li>Bromocriptine (theoretical)<\/li><li>Budesonide (theoretical)<\/li><li>Buprenorphine (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Buspirone (theoretical)<\/li><li>Cabazitaxel (theoretical)<\/li><li>Cabozantinib (theoretical)<\/li><li>Captopril (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Carvedilol (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clonazepam (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Cyclophosphamide (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Daclatasvir (theoretical)<\/li><li>Darifenacin (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Dexlansoprazole (theoretical)<\/li><li>Digoxin (theoretical)<\/li><li>Dihydroergotamine (theoretical)<\/li><li>Diltiazem (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Docetaxel (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Dolutegravir (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Dutasteride (theoretical)<\/li><li>Efavirenz (theoretical)<\/li><li>Eletriptan (theoretical)<\/li><li>Eliglustat (theoretical)<\/li><li>Elvitegravir (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Eplerenone (theoretical)<\/li><li>Ergotamine (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Esomeprazole (theoretical)<\/li><li>Estradiol (theoretical)<\/li><li>Eszopiclone (theoretical)<\/li><li>Ethinyl Estradiol (theoretical)<\/li><li>Etravirine (theoretical)<\/li><li>Everolimus (theoretical)<\/li><li>Exemestane (theoretical)<\/li><li>Felodipine (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Fexofenadine (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Fluticasone (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Fosamprenavir (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydrocodone (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Irinotecan (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ivacaftor (theoretical)<\/li><li>Ketoconazole (established)<\/li><li>Lansoprazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Letrozole (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Levonorgestrel (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Loperamide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Losartan (theoretical)<\/li><li>Lovastatin (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Lurasidone (theoretical)<\/li><li>Maraviroc (theoretical)<\/li><li>Medroxyprogesterone (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Midazolam (probable)<\/li><li>Mifepristone (theoretical)<\/li><li>Mirtazapine (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Montelukast (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Naloxegol (theoretical)<\/li><li>Nateglinide (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Netupitant (theoretical)<\/li><li>Nifedipine (theoretical)<\/li><li>Nimodipine (theoretical)<\/li><li>Nintedanib (theoretical)<\/li><li>Nisoldipine (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olaparib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Omeprazole (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Ospemifene (theoretical)<\/li><li>Oxycodone (theoretical)<\/li><li>Paclitaxel (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pantoprazole (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Perampanel (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Ponatinib (theoretical)<\/li><li>Prednisolone (theoretical)<\/li><li>Prednisone (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Propranolol (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quercetin (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Rabeprazole (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Regorafenib (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (established)<\/li><li>Rifapentine (theoretical)<\/li><li>Rilpivirine (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Roflumilast (theoretical)<\/li><li>Romidepsin (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Saxagliptin (theoretical)<\/li><li>Selegiline (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sildenafil (theoretical)<\/li><li>Silodosin (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Simvastatin (theoretical)<\/li><li>Sirolimus (theoretical)<\/li><li>Sitagliptin (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Suvorexant (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Talinolol (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Tamsulosin (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Temsirolimus (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Theophylline (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Tocophersolan (theoretical)<\/li><li>Tofacitinib (theoretical)<\/li><li>Tolvaptan (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Triamcinolone (theoretical)<\/li><li>Triazolam (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Ulipristal (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Verapamil (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Vinblastine (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Warfarin (theoretical)<\/li><li>Zaleplon (theoretical)<\/li><li>Zileuton (theoretical)<\/li><li>Zolpidem (theoretical)<\/li><\/ul>"},{"id":"928915-s-4-15","title":"Moderate","mono":"<ul>Pioglitazone (probable)<\/ul>"}]},{"id":"928915-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Peripheral edema (9% to 15%)<\/li><li><b>Dermatologic:<\/b>Alopecia (11% to 13%), Night sweats (12% to 27%), Pruritus (21% to 32%), Rash (36% to 38%)<\/li><li><b>Endocrine metabolic:<\/b>Hyponatremia (1% to 7%), Hypophosphatemia (8% to 17%), Serum cholesterol raised (28%), Serum triglycerides raised (10% to 12% or more)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (15% to 16%), Constipation (20% to 26%), Diarrhea (19% to 28%), Nausea (22% to 37%), Upper abdominal pain (12% to 18%), Vomiting (15% to 29%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (16% to 26%), Muscle weakness (1% to less than 10%), Myalgia (16% to 19%), Spasm, Muscle (12% to 15%)<\/li><li><b>Neurologic:<\/b>Asthenia (7% to 16%), Headache (20% to 35%)<\/li><li><b>Respiratory:<\/b>Cough (17% to 27%), Nasopharyngitis (15% to 27%)<\/li><li><b>Other:<\/b>Fatigue (6% to 32%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Ischemic heart disease (5% to 9.4%), Myocardial infarction (0.1% to less than 1%), Peripheral arterial occlusive disease (2.9% to 3.6%), Prolonged QT interval (Less than 1% to less than 10%)<\/li><li><b>Endocrine metabolic:<\/b>Decreased albumin, Grade 3 or 4 (up to 4%), Hyperglycemia (6% to 12%), Hypokalemia (up to 9%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal hemorrhage (2.9% to 5.1%), Increased serum lipase level (28%)<\/li><li><b>Hematologic:<\/b>Anemia, Grade 3 or 4 (4% to 27%), Febrile neutropenia (1% to less than 10%), Hemorrhage, Grade 3 or 4 (1.1% to 1.8%), Leukopenia (1% to less than 10%), Neutropenia, Grade 3 or 4 (12% to 42%), Thrombocytopenia, Grade 3 or 4 (10% to 42%)<\/li><li><b>Hepatic:<\/b>Alkaline phosphatase raised (up to 1%), ALT\/SGPT level raised (4%), AST\/SGOT level raised (1% to 3%), Serum bilirubin raised (4% to 9%)<\/li><li><b>Neurologic:<\/b>Cerebral infarction (0.1% to less than 1%), Cerebral ischemia (1.4% to 3.2%), Intracranial hemorrhage (1% to less than 10%), Ischemic stroke (0.1% to Less than 1%), Transient ischemic attack (0.1% to less than 1%)<\/li><li><b>Respiratory:<\/b>Pneumonia (less than 10%)<\/li><li><b>Other:<\/b>Fever (13% to 28%), Tumor lysis syndrome<\/li><\/ul>"},{"id":"928915-s-6","title":"Drug Name Info","sub":{"0":{"id":"928915-s-6-17","title":"US Trade Names","mono":"Tasigna<br\/>"},"2":{"id":"928915-s-6-19","title":"Class","mono":"<ul><li>Antineoplastic Agent<\/li><li>Tyrosine Kinase Inhibitor<\/li><\/ul>"},"3":{"id":"928915-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928915-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"928915-s-7","title":"Mechanism Of Action","mono":"Nilotinib monohydrochloride, a selective tyrosine kinase inhibitor, binds to and stabilizes the inactive conformation of the kinase domain of Abl protein. Bcr-Abl is the oncogenic tyrosine kinase expressed by Philadelphia chromosome-positive (Ph+) stem cells, directly involved in the pathogenesis of chronic myeloid leukemia (CML). Nilotinib inhibits the autophosphorylation of Bcr-Abl, PDGFR, and c-Kit, thereby reducing the tumor size. It has also demonstrated activity in the case of CML resistance to treatment with imatinib.<br\/>"},{"id":"928915-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"928915-s-8-23","title":"Absorption","mono":"<ul><li>Oral: rapid, reach peak concentration in 3 hours<\/li><li>Effect of food: (Oral), increase AUC by 82%<\/li><\/ul>"},"2":{"id":"928915-s-8-25","title":"Metabolism","mono":"<ul><li>oxidation and hydroxylation<\/li><li>Hepatic; CYP3A4<\/li><\/ul>"},"3":{"id":"928915-s-8-26","title":"Excretion","mono":"Fecal: 93% <br\/>"},"4":{"id":"928915-s-8-27","title":"Elimination Half Life","mono":"Adults: approximately 17 hours <br\/>"}}},{"id":"928915-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take on an empty stomach (avoid food for at least 2 hours before and at least 1 hour after taking nilotinib)<\/li><li>swallow capsules whole with water<\/li><li>for patients unable to swallow whole capsules; each capsule may be dispersed in 1 teaspoon of applesauce and consumed immediately<\/li><li>administer nilotinib 2 hours before or 2 hours after concurrent antacid<\/li><li>administer nilotinib 10 hours after a dose of an H2 blocker (eg, famotidine) and at least 2 hours before next dose of H2 blocker<\/li><\/ul>"},{"id":"928915-s-10","title":"Monitoring","mono":"<ul><li>Accelerated phase chronic myeloid leukemia, resistant or intolerant to prior therapy: hematologic response indicates efficacy<\/li><li>Chronic phase chronic myeloid leukemia, Philadelphia chromosome-positive, newly diagnosed: major molecular and cytogenetic responses indicate efficacy<\/li><li>Chronic phase chronic myeloid leukemia, resistant or intolerant to prior therapy: cytogenetic response indicates efficacy<\/li><li>Patients with total gastrectomy; monitor more frequently<\/li><li>Electrolytes (ie, phosphate, sodium, magnesium, potassium, and calcium levels); prior to therapy and periodically during therapy<\/li><li>Serum lipase levels, especially in patients with a history of pancreatitis; monthly or as clinically indicated<\/li><li>Hepatic function tests (ie, bilirubin and transaminase levels); monthly or as clinically indicated<\/li><li>CBC; every 2 weeks for the first 2 months of therapy, and monthly thereafter, or as clinically indicated  (including differential)<\/li><li>Glucose level and lipid panel; prior to initiating, periodically during first year of therapy, and at least annually during chronic use, or as clinically indicated<\/li><li>Signs and symptoms of tumor lysis syndrome; especially in patients at risk of tumor lysis syndrome or with large tumor burden<\/li><li>ECG, especially in patients with hepatic impairment; baseline, 7 days following therapy initiation, following dose adjustments, and periodically thereafter<\/li><li>Cardiovascular status and risk factors, according to standard guidelines; during treatment<\/li><li>Signs of severe fluid retention; during treatment<\/li><li>Symptoms of respiratory compromise; during treatment<\/li><\/ul>"},{"id":"928915-s-11","title":"How Supplied","mono":"<b>Tasigna<\/b><br\/>Oral Capsule: 150 MG, 200 MG<br\/>"},{"id":"928915-s-12","title":"Toxicology","sub":[{"id":"928915-s-12-31","title":"Clinical Effects","mono":"<b>NILOTINIB<\/b><br\/>OVERDOSE: No reported nilotinib overdose information at the time of this review. The signs and symptoms of an acute overdose are expected to be similar to excessive pharmacologic effects, including myelosuppression, and QTc prolongation with the potential for ventricular dysrhythmias. ADVERSE EFFECTS: The most common adverse effects, following therapeutic administration of nilotinib, include rash, pruritus, nausea, vomiting, diarrhea, constipation, fatigue, and headache. Myelosuppression, including anemia, neutropenia, and thrombocytopenia, and QT interval prolongation have also been reported. <br\/>"},{"id":"928915-s-12-32","title":"Treatment","mono":"<b>NILOTINIB <\/b><br\/><ul><li>Support: In case of overdose, treatment is symptomatic and supportive.<\/li><li>Decontamination: Consider activated charcoal after a potentially toxic ingestion if the patient is able to maintain airway or if airway is protected.<\/li><li>Myelosuppression: There is little data on the use of hematopoietic colony stimulating factors to treat neutropenia. It may be considered in patients with neutropenia at significant risk for developing febrile neutropenia. Filgrastim: Adult: Starting dose is 5 mcg\/kg\/day by IV infusion or subQ injection. Sargramostim: Usual dose 250 mcg\/square meter\/day infused IV over 4 hrs. Packed red cell and\/or platelet transfusion may be needed in patients with severe thrombocytopenia, anemia, or hemorrhage.<\/li><li>Torsades de pointes: Not reported, but may develop secondary to QTc prolongation. Correct hypocalcemia and hypophosphatemia. Administer intravenous MAGNESIUM SULFATE. ADULT: 2 g IV over 1 to 2 min, repeat 2 g bolus and begin infusion of 0.5 to 1 g\/hr if dysrhythmias recur. CHILDREN: 25 to 50 mg\/kg diluted to 10 mg\/mL; infuse IV over 5 to 15 min. Overdrive pacing may be needed.<\/li><li>Monitoring of patient: Monitor serial CBC with differential, platelet count, and hepatic enzymes after significant overdose. Monitor fluid and electrolyte status after acute overdose and in patients with severe vomiting and\/or diarrhea. Institute continuous cardiac monitoring and obtain serial ECGs to evaluate for QT interval prolongation.<\/li><li>Enhanced elimination procedure: Due to the high protein binding of nilotinib, hemodialysis is not expected to be an effective method of enhanced elimination.<\/li><\/ul>"},{"id":"928915-s-12-33","title":"Range of Toxicity","mono":"<b>NILOTINIB<\/b><br\/>TOXICITY: No overdose information available. THERAPEUTIC DOSE: The recommended dose of nilotinib in adult patients is 400 mg orally every 12 hours. <br\/>"}]},{"id":"928915-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to immediately report symptoms of cardiovascular events (QT prolongation, ischemic heart or cerebrovascular events, peripheral arterial occlusion).<\/li><li>Warn patient to report symptoms of myelosuppression (anemia, neutropenia, thrombocytopenia).<\/li><li>Side effects may include rash, pruritus, fatigue, alopecia, myalgia, arthralgia, nausea, diarrhea, and constipation.<\/li><li>Warn patient to report symptoms of pancreatitis.<\/li><li>Advise patient to avoid food 2 hours before and 1 hour after taking drug.<\/li><li>Warn patient that grapefruit products should not be consumed with drug.<\/li><li>In the event of a missed dose, counsel patient to skip the missed dose and maintain a regular dosing schedule without doubling the dose.<\/li><\/ul>"}]}